Paul Varley is a seasoned professional in biopharmaceutical development, currently serving as Senior Vice President of Development at Alchemab Therapeutics Ltd since September 2021. Prior to this role, Varley held significant positions including Vice President of Biopharmaceutical Development at Kymab Ltd and MedImmune, where responsibilities included leading CMC project teams from preclinical stages to late-phase development. Varley began their career at British Biotech as Head of Protein Sciences and has extensive experience in CMC development, being a member of various senior leadership teams. Varley earned a PhD in Biochemistry, Biophysics, and Molecular Biology from Newcastle University and a First Class BSc in Molecular Biophysics from the University of Portsmouth.